vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and UNIVERSAL HEALTH REALTY INCOME TRUST (UHT). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $24.5M, roughly 1.4× UNIVERSAL HEALTH REALTY INCOME TRUST). UNIVERSAL HEALTH REALTY INCOME TRUST runs the higher net margin — 17.7% vs -299.9%, a 317.6% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -0.7%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -1.3%).
Universal Health Services, Inc. (UHS) is an American Fortune 500 company that provides hospital and healthcare services, based in King of Prussia, Pennsylvania. In 2024, UHS reported total revenues of $15.8 billion.
KPTI vs UHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $24.5M |
| Net Profit | $-102.2M | $4.3M |
| Gross Margin | — | — |
| Operating Margin | -52.4% | 34.7% |
| Net Margin | -299.9% | 17.7% |
| Revenue YoY | 11.6% | -0.7% |
| Net Profit YoY | -232.0% | -7.2% |
| EPS (diluted) | $-7.02 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $24.5M | ||
| Q3 25 | $44.0M | $25.3M | ||
| Q2 25 | $37.9M | $24.9M | ||
| Q1 25 | $30.0M | $24.5M | ||
| Q4 24 | $30.5M | $24.6M | ||
| Q3 24 | $38.8M | $24.5M | ||
| Q2 24 | $42.8M | $24.7M | ||
| Q1 24 | $33.1M | $25.1M |
| Q4 25 | $-102.2M | $4.3M | ||
| Q3 25 | $-33.1M | $4.0M | ||
| Q2 25 | $-37.3M | $4.5M | ||
| Q1 25 | $-23.5M | $4.8M | ||
| Q4 24 | $-30.8M | $4.7M | ||
| Q3 24 | $-32.1M | $4.0M | ||
| Q2 24 | $23.8M | $5.3M | ||
| Q1 24 | $-37.4M | $5.3M |
| Q4 25 | -52.4% | 34.7% | ||
| Q3 25 | -34.6% | 33.2% | ||
| Q2 25 | -64.3% | 35.6% | ||
| Q1 25 | -110.8% | 36.8% | ||
| Q4 24 | -102.4% | 37.6% | ||
| Q3 24 | -67.8% | 34.7% | ||
| Q2 24 | -65.7% | 38.7% | ||
| Q1 24 | -101.9% | 37.6% |
| Q4 25 | -299.9% | 17.7% | ||
| Q3 25 | -75.2% | 15.9% | ||
| Q2 25 | -98.2% | 18.1% | ||
| Q1 25 | -78.2% | 19.5% | ||
| Q4 24 | -100.8% | 18.9% | ||
| Q3 24 | -82.7% | 16.3% | ||
| Q2 24 | 55.6% | 21.3% | ||
| Q1 24 | -112.8% | 21.1% |
| Q4 25 | $-7.02 | $0.32 | ||
| Q3 25 | $-3.82 | $0.29 | ||
| Q2 25 | $-4.32 | $0.32 | ||
| Q1 25 | $-2.77 | $0.34 | ||
| Q4 24 | $-2.33 | $0.34 | ||
| Q3 24 | $-3.85 | $0.29 | ||
| Q2 24 | $-2.97 | $0.38 | ||
| Q1 24 | $-4.85 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $6.7M |
| Total DebtLower is stronger | — | $374.8M |
| Stockholders' EquityBook value | $-292.9M | $152.4M |
| Total Assets | $108.4M | $564.9M |
| Debt / EquityLower = less leverage | — | 2.46× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $6.7M | ||
| Q3 25 | $37.7M | $6.9M | ||
| Q2 25 | $38.7M | $6.6M | ||
| Q1 25 | $38.8M | $7.0M | ||
| Q4 24 | $62.5M | $7.1M | ||
| Q3 24 | $72.8M | $6.4M | ||
| Q2 24 | $84.8M | $5.6M | ||
| Q1 24 | $30.6M | $7.7M |
| Q4 25 | — | $374.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $368.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-292.9M | $152.4M | ||
| Q3 25 | $-269.3M | $158.6M | ||
| Q2 25 | $-238.9M | $165.2M | ||
| Q1 25 | $-205.9M | $172.2M | ||
| Q4 24 | $-186.0M | $179.5M | ||
| Q3 24 | $-159.6M | $181.6M | ||
| Q2 24 | $-132.1M | $190.7M | ||
| Q1 24 | $-169.0M | $196.5M |
| Q4 25 | $108.4M | $564.9M | ||
| Q3 25 | $96.2M | $568.0M | ||
| Q2 25 | $104.9M | $573.0M | ||
| Q1 25 | $127.7M | $573.5M | ||
| Q4 24 | $164.4M | $580.9M | ||
| Q3 24 | $189.5M | $584.3M | ||
| Q2 24 | $214.0M | $586.6M | ||
| Q1 24 | $204.5M | $596.2M |
| Q4 25 | — | 2.46× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $49.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 11.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $49.1M | ||
| Q3 25 | $-5.9M | $10.2M | ||
| Q2 25 | $-18.7M | $13.7M | ||
| Q1 25 | $-39.0M | $11.6M | ||
| Q4 24 | $-25.8M | $46.9M | ||
| Q3 24 | $-19.5M | $9.9M | ||
| Q2 24 | $-38.5M | $12.1M | ||
| Q1 24 | $-43.7M | $11.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-25.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-43.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -84.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -132.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | 11.35× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 3.05× | ||
| Q1 25 | — | 2.43× | ||
| Q4 24 | — | 10.06× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | -1.62× | 2.30× | ||
| Q1 24 | — | 2.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
UHT
| Reportable Segment Aggregation Before Other Operating Segment | $23.1M | 94% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $2.3M | 9% |
